Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Purpose: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA. Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways. PARP inhibitors are emerging as a new class of agents that can potentiate chemot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2008-12, Vol.14 (23), p.7917-7923
Hauptverfasser:	Plummer, Ruth, Jones, Christopher, Middleton, Mark, Wilson, Richard, Evans, Jeffrey, Olsen, Anna, Curtin, Nicola, Boddy, Alan, McHugh, Peter, Newell, David, Harris, Adrian, Johnson, Patrick, Steinfeldt, Heidi, Dewji, Raz, Wang, Diane, Robson, Lesley, Calvert, Hilary
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use chemopotentiation Comet Assay Cytochrome P-450 CYP2D6 - genetics Dacarbazine - administration & dosage Dacarbazine - adverse effects Dacarbazine - analogs & derivatives DNA Breaks - drug effects DNA repair Female Humans Indoles - administration & dosage Indoles - adverse effects Indoles - pharmacokinetics Male Middle Aged Neoplasms - drug therapy Neoplasms - genetics PARP inhibitor pharmacodynamics Temozolomide
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!